Outset Medical, Inc. (OM) Stock Analysis and Metrics

Outset Medical

NASDAQ: OM

$4.38 ▲ +0.34 (+8.29%)

At close: Jul 27, 2026 · 3:44 PM UTC

Financial Ratios

Market Cap80,381.88

P/E0.00

P/S0.00

Div. Yield0.00

Total Debt (Qtr)96.94 Mn

Revenue Growth (1y) (Qtr)-6.35

Add ratio to table…

About

Outset is a medical technology company pioneering a first of its kind technology to improve clinical outcomes in dialysis with less cost and complexity. The company's flagship product, the Tablo Hemodialysis System, integrates water purification, on demand dialysate production, and data connectivity into a single compact console. Designed for use across hospital, clinic, and home settings, Tablo enables dialysis delivery anytime, anywhere, and by virtually any trained user. The Tablo system has received clearance from the U. S. Food and Drug Administration for use in hospital, clinic, and home settings, underscoring its regulatory compliance and readiness for broad adoption.

Outset generates revenue primarily from the sale of Tablo consoles and the recurring sale of disposable cartridges required for each treatment. The company also offers service contracts, training programs, and data analytics subscriptions that support the Tablo ecosystem. Its customers are dialysis providers, including hospitals, outpatient clinics, skilled nursing facilities, and home care programs, who purchase or lease the system to deliver therapy to patients. Service revenue includes field support, remote monitoring, and preventive maintenance, which are delivered through the company’s dedicated service team. Outset sells its products directly to dialysis providers and also works with distribution partners to expand its reach.

Outset competes in the dialysis equipment market against established players such as Fresenius Medical Care, DaVita (through its Mozarc joint venture), B. Braun, and Quanta Dialysis Technologies. Its competitive advantage lies in offering a single platform that can be used in acute, chronic, and home environments, reducing the need for multiple machines and associated infrastructure. The system’s ease of use, shortened setup time, and integrated data analytics capabilities further differentiate it from traditional dialysis equipment. Clinical studies have shown that Tablo reduces treatment setup time from approximately 45 minutes to under 20 minutes, contributing to greater staff efficiency. The platform’s integrated cloud connectivity enables real time device monitoring, predictive maintenance, and automated documentation, which lowers operational costs for providers.

Outset serves a broad range of dialysis providers, including acute care hospitals, chronic dialysis clinics, skilled nursing facilities, long term acute care hospitals, and home based patients. While the filing does not disclose specific customer names, the company notes that it has worked with nearly 1,000 acute care facilities to support insourced dialysis programs. The company’s recurring revenue depends on the ongoing purchase of cartridges and service agreements by these providers. As of the end of 2025, the company reported an installed base of several thousand Tablo units across the United States. Outset continues to invest in sales and field service personnel to support adoption and maintain high customer satisfaction.

Investment Thesis

▲ Bull case

Outset Medical is positioned to leverage its next-generation Tablo platform as a transformative catalyst in 2026, with the FDA clearance representing a significant competitive advantage in an industry where cybersecurity has become a critical patient safety priority. The company’s leadership emphasized that the new platform’s secure-by-design architecture and compliance with FDA’s rigorous cybersecurity standards address a top concern for health systems, especially given that 93% of healthcare organizations experienced at least one cyberattack in the past year according to industry surveys. This positioning could drive incremental demand across hospital sizes, as cybersecurity concerns are uniformly heightened regardless of facility scale, potentially shortening sales cycles by aligning with urgent institutional priorities around continuity of care and patient safety. The upgrade opportunity for the existing installed base of roughly 1,000 acute care sites creates a near-term revenue tailwind that management acknowledged but did not fully quantify, suggesting upside to current guidance if adoption accelerates faster than anticipated. Furthermore, the company’s deepening relationships with critical access hospitals—where dialysis clinic closures are creating unmet need in rural communities—represent an underserved expansion vector that aligns with both clinical mission and reimbursement trends favoring localized care delivery. With recurring revenue growing 6% year-over-year in 2025 and the company guiding for 5% to 9% total revenue growth in 2026, the combination of an expanding installed base, higher-margin consumable revenue, and the cybersecurity-driven value proposition could enable gross margin expansion toward the 50% long-term target sooner than currently modeled, especially as manufacturing under-absorption headwinds attenuate. The $173 million cash balance provides ample runway to fund commercial execution without dilution, supporting sustained investment in sales and service infrastructure to capture pipeline opportunities.
The company’s progress in gross margin expansion reflects a structural shift in profitability drivers rather than a temporary recovery, with non-GAAP gross margin increasing 400 basis points for the full year 2025 to 39.6% and product gross margin exceeding 50% for the first time in Q4. This trend is underpinned by meaningful operating leverage, as non-GAAP operating expenses declined 19% year-over-year while revenue grew 5%, demonstrating disciplined cost management even as investments in innovation and commercial execution continued. Management’s commentary on operating leverage—anticipating operating expense growth at roughly half the rate of sales growth in 2026—suggests that each incremental dollar of revenue will contribute disproportionately to bottom-line improvement, accelerating the path to cash flow breakeven and profitability. The depth of Outset’s data assets, with over 8 trillion data points in its cloud platform, creates a durable moat by enabling predictive analytics, service optimization, and innovation cycles that competitors cannot easily replicate, directly enhancing customer retention and expansion potential. This data advantage, combined with the clinical value proposition gaining traction—evidenced by customer-reported reductions in infection rates, length of stay, and nurse satisfaction—shifts the sales conversation from pure cost savings to broader value-based outcomes, which resonates strongly with value-based care initiatives and accountable care organizations. The pipeline’s diversification across new and existing customers, as well as hospital size (from critical access systems to large health systems), indicates resilient demand less vulnerable to concentration risk, while the sales force’s stability despite leadership transitions suggests operational continuity that could support consistent execution. These factors collectively imply that the market may be underestimating the durability of Outset’s competitive position and the scalability of its model as it transitions from growth investment to profitable scale.

Outset Medical is positioned to leverage its next-generation Tablo platform as a transformative catalyst in 2026, with the FDA clearance representing a significant competitive advantage in an industry where cybersecurity has become a critical patient safety priority. The company’s leadership emphasized that the new platform’s secure-by-design architecture and compliance with FDA’s rigorous cybersecurity standards address a top concern for health systems, especially given that 93% of healthcare organizations experienced at least one cyberattack in the past year according to industry surveys. This positioning could drive incremental demand across hospital sizes, as cybersecurity concerns are uniformly heightened regardless of facility scale, potentially shortening sales cycles by aligning with urgent institutional priorities around continuity of care and patient safety. The upgrade opportunity for the existing installed base of roughly 1,000 acute care sites creates a near-term revenue tailwind that management acknowledged but did not fully quantify, suggesting upside to current guidance if adoption accelerates faster than anticipated. Furthermore, the company’s deepening relationships with critical access hospitals—where dialysis clinic closures are creating unmet need in rural communities—represent an underserved expansion vector that aligns with both clinical mission and reimbursement trends favoring localized care delivery. With recurring revenue growing 6% year-over-year in 2025 and the company guiding for 5% to 9% total revenue growth in 2026, the combination of an expanding installed base, higher-margin consumable revenue, and the cybersecurity-driven value proposition could enable gross margin expansion toward the 50% long-term target sooner than currently modeled, especially as manufacturing under-absorption headwinds attenuate. The $173 million cash balance provides ample runway to fund commercial execution without dilution, supporting sustained investment in sales and service infrastructure to capture pipeline opportunities.
The company’s progress in gross margin expansion reflects a structural shift in profitability drivers rather than a temporary recovery, with non-GAAP gross margin increasing 400 basis points for the full year 2025 to 39.6% and product gross margin exceeding 50% for the first time in Q4. This trend is underpinned by meaningful operating leverage, as non-GAAP operating expenses declined 19% year-over-year while revenue grew 5%, demonstrating disciplined cost management even as investments in innovation and commercial execution continued. Management’s commentary on operating leverage—anticipating operating expense growth at roughly half the rate of sales growth in 2026—suggests that each incremental dollar of revenue will contribute disproportionately to bottom-line improvement, accelerating the path to cash flow breakeven and profitability. The depth of Outset’s data assets, with over 8 trillion data points in its cloud platform, creates a durable moat by enabling predictive analytics, service optimization, and innovation cycles that competitors cannot easily replicate, directly enhancing customer retention and expansion potential. This data advantage, combined with the clinical value proposition gaining traction—evidenced by customer-reported reductions in infection rates, length of stay, and nurse satisfaction—shifts the sales conversation from pure cost savings to broader value-based outcomes, which resonates strongly with value-based care initiatives and accountable care organizations. The pipeline’s diversification across new and existing customers, as well as hospital size (from critical access systems to large health systems), indicates resilient demand less vulnerable to concentration risk, while the sales force’s stability despite leadership transitions suggests operational continuity that could support consistent execution. These factors collectively imply that the market may be underestimating the durability of Outset’s competitive position and the scalability of its model as it transitions from growth investment to profitable scale.

▼ Bear case

Despite the positive narrative around the next-generation Tablo platform, Outset Medical faces significant execution risks in converting its cybersecurity advantage into meaningful revenue acceleration, particularly given the lack of specific ASP guidance or upgrade pricing details from management during the Q&A. The company acknowledged that the commercial launch will occur late Q2, meaning only half the year will benefit from the new platform’s full commercial impact, and any initial uptake from the installed base upgrade program may be slower than anticipated due to hospital budget cycles, capital approval processes, or competing priorities in an environment of ongoing financial pressure. Furthermore, while cybersecurity is a growing concern, it remains one of many factors in hospital purchasing decisions, and there is no evidence yet that it will meaningfully shorten sales cycles or increase win rates—especially for large enterprise deals where Leslie Trigg noted cycles can extend to 1.5 years due to multi-stakeholder alignment. The company’s reliance on anecdotal customer feedback about clinical benefits (e.g., reduced infection rates, length of stay) lacks the scale of prospective, randomized data that would be required to drive broad formulary or contract changes, making it difficult to translate early adopter success into systemic market expansion. Without clear evidence that the next-gen Tablo will command a premium ASP or significantly increase utilization per console, the expected gross margin expansion may be delayed, leaving the company vulnerable to missing its low-to-mid-40% gross margin guidance for 2026 if manufacturing mix shifts unfavorably or if console sales growth outpaces higher-margin consumable adoption.
Outset Medical’s path to profitability remains contingent on sustained operating leverage, yet the business model continues to burn cash despite progress, with $46 million used in 2025 and guidance implying only a modest reduction in cash use for 2026. The $173 million cash balance, while seemingly ample, provides less than four years of runway at the current burn rate, and any slowdown in revenue growth or unexpected increase in operating expenses—such as those tied to sales force expansion, service infrastructure scaling, or regulatory compliance for the new platform—could rapidly erode this buffer. The ongoing investigation by Halper Sadeh LLC into potential fiduciary breaches by officers and directors introduces material overhang and reputational risk, potentially distracting management, increasing legal and compliance costs, and triggering investor skepticism that could weigh on the stock independent of fundamentals. Additionally, the company’s guidance assumes a 5% to 9% revenue increase in 2026, but this range implies growth at or below the prior year’s 5% increase, suggesting a lack of meaningful acceleration despite the new product launch and expanding pipeline. This stagnation in top-line momentum raises concerns about market saturation in the acute care dialysis segment or slower-than-expected adoption of in-sourcing models, particularly if hospitals continue to favor outsourcing due to perceived operational simplicity or if reimbursement policies fail to adequately incentivize in-sourcing. The lack of discussion around pricing pressure from larger dialysis providers or potential commoditization of console-based systems further underscores a vulnerability: if competitors respond with lower-cost alternatives or bundled service offerings, Outset may be forced into discounting that undermines its gross margin targets, especially as it scales beyond its current niche of innovation-focused early adopters.

Despite the positive narrative around the next-generation Tablo platform, Outset Medical faces significant execution risks in converting its cybersecurity advantage into meaningful revenue acceleration, particularly given the lack of specific ASP guidance or upgrade pricing details from management during the Q&A. The company acknowledged that the commercial launch will occur late Q2, meaning only half the year will benefit from the new platform’s full commercial impact, and any initial uptake from the installed base upgrade program may be slower than anticipated due to hospital budget cycles, capital approval processes, or competing priorities in an environment of ongoing financial pressure. Furthermore, while cybersecurity is a growing concern, it remains one of many factors in hospital purchasing decisions, and there is no evidence yet that it will meaningfully shorten sales cycles or increase win rates—especially for large enterprise deals where Leslie Trigg noted cycles can extend to 1.5 years due to multi-stakeholder alignment. The company’s reliance on anecdotal customer feedback about clinical benefits (e.g., reduced infection rates, length of stay) lacks the scale of prospective, randomized data that would be required to drive broad formulary or contract changes, making it difficult to translate early adopter success into systemic market expansion. Without clear evidence that the next-gen Tablo will command a premium ASP or significantly increase utilization per console, the expected gross margin expansion may be delayed, leaving the company vulnerable to missing its low-to-mid-40% gross margin guidance for 2026 if manufacturing mix shifts unfavorably or if console sales growth outpaces higher-margin consumable adoption.
Outset Medical’s path to profitability remains contingent on sustained operating leverage, yet the business model continues to burn cash despite progress, with $46 million used in 2025 and guidance implying only a modest reduction in cash use for 2026. The $173 million cash balance, while seemingly ample, provides less than four years of runway at the current burn rate, and any slowdown in revenue growth or unexpected increase in operating expenses—such as those tied to sales force expansion, service infrastructure scaling, or regulatory compliance for the new platform—could rapidly erode this buffer. The ongoing investigation by Halper Sadeh LLC into potential fiduciary breaches by officers and directors introduces material overhang and reputational risk, potentially distracting management, increasing legal and compliance costs, and triggering investor skepticism that could weigh on the stock independent of fundamentals. Additionally, the company’s guidance assumes a 5% to 9% revenue increase in 2026, but this range implies growth at or below the prior year’s 5% increase, suggesting a lack of meaningful acceleration despite the new product launch and expanding pipeline. This stagnation in top-line momentum raises concerns about market saturation in the acute care dialysis segment or slower-than-expected adoption of in-sourcing models, particularly if hospitals continue to favor outsourcing due to perceived operational simplicity or if reimbursement policies fail to adequately incentivize in-sourcing. The lack of discussion around pricing pressure from larger dialysis providers or potential commoditization of console-based systems further underscores a vulnerability: if competitors respond with lower-cost alternatives or bundled service offerings, Outset may be forced into discounting that undermines its gross margin targets, especially as it scales beyond its current niche of innovation-focused early adopters.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	182.52 Bn	29.08	4.04	34.05 Bn
2	SYK	Stryker Corp	128.96 Bn	38.65	5.10	14.72 Bn
3	MDT	Medtronic plc	107.99 Bn	22.32	2.97	27.96 Bn
4	BSX	Boston Scientific Corp	67.76 Bn	19.01	3.29	11.03 Bn
5	EW	Edwards Lifesciences Corp	48.09 Bn	2,334.23	7.63	0.60 Bn
6	DXCM	Dexcom Inc	28.30 Bn	30.41	5.87	-
7	GEHC	GE HealthCare Technologies Inc.	27.89 Bn	14.11	1.33	10.14 Bn
8	SNN	Smith & Nephew Plc	27.02 Bn	161.82	4.19	3.18 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password